Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients

Figures & data

Table 1 Baseline characteristics and sustained virologic response rates in subjects randomized to pegylated interferon and ribavirin in four pivotal trials. Reprinted with permission from Shuhart MC. 2007. Hepatitis C and HIV coinfection. Curr Hepatitis Rep, 6:46–53. Copyright © 2005 Current Medicine Group LLC.

	APRICOT [45••]	Barcelona [46•]	ACTG [47•]	RIBAVIC [48•]
Subjects, N	289	52	66	205
Pegylated interferon	Alfa-2a	Alfa-2b	Alfa-2a	Alfa-2b
Ribavirin dose, mg/d	800	800, 1000 or 1200	600–1000 (escalated)	800
Age, y	39.7 (mean)	40 (mean)	45 (median)	39.5 (mean)
Male, %	80	63	79	77
African American, %	11	NR	32	NR*
Body weight, mean, kg	72.1	NR	NR	67.4
CD4 cell count, cells/μL	542 (mean)	570 (mean)	495 (median)	477 (median)
HIV RNA, % undetectable	60 (<50 copies/mL)	70 (<200 copies/mL)	61 (<50 copies/mU	70 (<400 copies/mL)
Antiretroviral therapy, %	84	88	85	83
HCV RNA level in high range, %	72 (>800,000 lU/mL)	47 (>800,000 IU/mL)	83 (>1,000,000 IU/mL)	65 (>500,000 IU/mL)
HCV genotype, %
Genotype 1	61	55	77	48
Genotype 2 or 3	32	37	NR^+	38
Genotype 4	6	8	NR^+	13
Other	1	0	NR^1	1
Bridging fibrosis/cirrhosis, %	12	30	11	39
Sustained response, %
Genotype 1	29	38*	14	17‡
Genotype 2 or 3	62	53	73†	44
Genotype 4	NR	—	—	—

* 6% not of French or Mediterranean descent.

† Non-1 genotypes were predominantly 2 or 3.

‡ Genotypes 1 and 4 combined.

Abbreviations: ACTC, AIDS Clinical Trials Croup; APRICOT, AIDS PECASYS Ribavirin International Co-infection Trial; HCV, hepatitis C virus; NR, not reported.